OncoResponse Announces Two Poster Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023)
SEATTLE, Washington – October 26, 2023 – OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego.
Details are as follows:
Title: OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses
Abstract Number: 494
Details: Saturday, November 4, 2023, in the Poster Hall 9 a.m. to 8:30 p.m. PDT (Reception 7 p.m. to 8:30 p.m. PDT)
Title: OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response
Abstract Number: 519
Details: Friday, November 3, 2023, in the Poster Hall 9 a.m. to 7 p.m. PDT (Reception 5:10 p.m. to 6:40 p.m. PDT)
About OncoResponse
OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Cancer Responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. The company’s lead clinical candidate, OR502 is a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression and has entered clinical study in 2023. OR2805 is a fully human antibody discovered using B cells derived from an Elite Responder to checkpoint inhibitor (CPI) therapy currently in cohort expansion trials for multiple cancer indications. OR641 is a unique dual anti-LILRB2/1 antagonist antibody that promotes a Th1-like immune response. Additional pipeline candidates that modulate suppressive macrophage activity are under development. For more information, please visit www.oncoresponse.com and follow us on LinkedIn and X.
Media Contact:
Julie Rathbun
Rathbun Communications
+1.206.769.9219
julie@rathbuncomm.com